Author of

• 25955

  +

  P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27450

    +

    P3.01-92 - Blood Test Parameters as Prognostic Factors In EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs (ID 12414)

    12:00 - 13:30  |  Author(s): Vera Jokic
    • Abstract

    Background
    

    Systemic inflammation is an important factor contributing to tumor progression. High neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of host inflammation whose association with worse overall survival (OS) in non-small cell lung cancer (NSCLC) has been shown in various studies. However, there are few studies investigating the association of these, and other haematological parameters of inflammation with prognosis of EGFR mutated NSCLC treated with tyrosine-kinase inhibitors (TKIs). We therefore examined the association between various blood test parameters and prognosis in this group of patients.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    This retrospective analysis included 74 consecutive advanced lung adenocarcinoma patients of caucasian descent, stage IIIB or IV, treated with EGFR TKIs in the first line at the Institute for oncology and radiology of Serbia within a five year period. The analysed haematological parameters were derived from the absolute differential counts of a complete blood count (CBC) taken within one week of TKI treatment initiation. Parameters included in this analysis were NLR, PLR, lymphocyte-to-monocyte ratio (LMR), mean platelet volume (MPV), lymphocyte-to-white blood cell ratio (LWR) and neutrophil-to-white blood cell ratio (NWR). Cut-off values were determined using ROC curves. Correlation between each haematological parameter and progression-free survival (PFS) and OS was examined by Kaplan-Meier method and Cox regression

    4c3880bb027f159e801041b1021e88e8 Result
    

    Median PFS in the whole group was 13.6 months (10.25-16.95, CI 95%) and median OS was 19.48 months (15.91-23.05, CI 95%). Low LWR (< 0.14) was associated with a shorter PFS in this group of patients (9.2 vs 14.29 months, p=0.008). High NLR (≥ 2.63), high MPV (≥ 8.1) and low LWR (< 0.14) were associated with shorter OS (18.0 vs 27.6 months, p=0.05; 15.57 vs 22.18 months, p=0.04 and 16.13 vs 22.19, p=0.038 respectively). No other analysed parameters showed an association with either PFS or OS

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Pre-treatment NLR, LWR and MPV could be reliable, simple and easy to reproduce parameters for prediction of survival and outcome of targeted therapies in caucasian EGFR-mutated NSCLC patients. Further prospective trials are needed to definitively confirm this possible prognostic and predictive role

    6f8b794f3246b0c1e1780bb4d4d5dc53